Overview

Study of the Pharmacokinetics and Safety of TPN171H Tablets in Subjects With Mild ,Moderate Hepatic Insufficiency and Normal Liver Function

Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The study aims to investigate and compare the effect of TPN171H on subjects with mild and moderate hepatic impairment compared to healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Vigonvita Life Sciences
Collaborator:
Shanghai Institute of Materia Medica, Chinese Academy of Sciences